Home » Newsletters » BioWorld Science

BioWorld Science

July 17, 2020

View Archived Issues

First multitope peptide-based vaccine against SARS-CoV-2 to enter clinical testing

Blood infrastructure problems contribute to ASD

Everyone's an immune cell

c-Myc overexpression used to create mouse-derived allograft model of hepatocellular carcinoma

SBIR grant supports Lamassu's development of RABI-767 for acute pancreatitis

Chinese clearance for global phase III trial of catumaxomab for peritoneal carcinomatosis

HFB-200301 shows potential as novel immunotherapeutic agent in vivo

BPI-28592, a novel potent next-generation TRK kinase inhibitor

Nexys Therapeutics presents new ALK5 inhibitors

Praxis Precision Medicines patents compounds targeting human KCNT1

SPRY1 targeting useful for treating BRAF V600-mutant cutaneous melanoma

Recce and Path BioAnalytics collaborate in expanded SARS-CoV-2 program

Surface Oncology describes preclinical activity of anti-PVRIG antibody SRF-813

Bcl-2/Bcl-xl dual inhibitor AZD-0466 shows promise for treating ALL

Heron initiates phase II GUARDS-1 study of Cinvanti for the treatment of COVID-19

Binding of MAO-A PET radiotracer [18F]FAZIN-3 observed in Parkinson's, Alzehimer's brain samples

NIH grant supports development of Vivasc's CTP-amio for arrhythmia

Dynavax and Mount Sinai collaborate to develop a universal influenza vaccine

Phase III trial begins in UAE for Sinopharm's inactivated vaccine for COVID-19

Xenleta approved in Canada for community-acquired pneumonia

Tracon files pivotal ENVASARC protocol with the FDA

Expansion of phase I study evaluating eprenetapopt in TP53-mutant AML

[18F]-FSPG PET can rule out cardiac sarcoidosis after nondiagnostic [18F]-FDG PET

Samus opens phase IIa trial of PU-AD for mild Alzheimer's disease dementia

Lilly reports OASIS-2 data with mirikizumab in moderate to severe plaque psoriasis

Celltrion advances antiviral antibody treatment for COVID-19 into phase I

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...